(Q35748692)

English

Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.

scientific article published on 5 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. (English)

1 reference

Europe PubMed Central

10 August 2017

Adaptive radiation therapy

0 references

Otto S Hoekstra

5

object named as

Otto S Hoekstra

1 reference

Europe PubMed Central

10 August 2017

Josée M Zijlstra

6

object named as

Josée M Zijlstra

1 reference

Europe PubMed Central

10 August 2017

Guus A M S van Dongen

8

object named as

Guus A M S van Dongen

1 reference

Europe PubMed Central

10 August 2017

author name string

Saiyada N F Rizvi

1

1 reference

Europe PubMed Central

10 August 2017

Otto J Visser

2

1 reference

Europe PubMed Central

10 August 2017

Maria J W D Vosjan

3

1 reference

Europe PubMed Central

10 August 2017

Arthur van Lingen

4

1 reference

Europe PubMed Central

10 August 2017

Peter C Huijgens

7

1 reference

Europe PubMed Central

10 August 2017

Mark Lubberink

9

1 reference

Europe PubMed Central

10 August 2017

publication date

5 January 2012

1 reference

Europe PubMed Central

10 August 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

10 August 2017

39

1 reference

Europe PubMed Central

10 August 2017

3

1 reference

Europe PubMed Central

10 August 2017

512-520

1 reference

Europe PubMed Central

10 August 2017

https://scigraph.springernature.com/pub.10.1007/s00259-011-2008-5

0 references

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

27 July 2018

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276758

25 September 2018

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2008-5

21 January 2018

A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonstochastic effects of ionizing radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22218876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-2008-5

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35748692&oldid=1952944522"